Is Cerebrolysin Safe? Safety Profile 2026 — PeptidePrices

Q: Is Cerebrolysin safe?

Cerebrolysin has a safety rating of 6/10 in our methodology — moderate. Used in Europe/Asia for stroke/TBI; some clinical trial data; not FDA-approved but prescribed widely abroad

Q: Is Cerebrolysin FDA approved?

FDA status: Approved in some countries. PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified Cerebrolysin?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest Cerebrolysin listings for prices ranked by COA tier and $/mg.

Safety Profile

Cerebrolysin

Updated today

Neurotrophic Peptide Mixture

6/10Moderate

How we score compound safety →

Primary use: Neurotrophic research

Regulatory Status

Approved in some countries

Safety Summary

Used in Europe/Asia for stroke/TBI
some clinical trial data
not FDA-approved but prescribed widely abroad

Cerebrolysin's 6/10 rating reflects mixed evidence — some clinical data and a meaningful research base, but enough open questions that researchers should weight personal risk tolerance heavily. Long-term safety in the population segment most likely to use this compound (off-label) is the area with the thinnest published evidence. Researchers often consider Semax and P21 Peptide as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypePorcine brain-derived peptide mixture

Molecular WeightLow-MW peptides <10 kDa + free amino acids

Amino AcidsMixture (not a single species)

CAS NumberNot applicable (mixture)

Storage

LyophilizedSupplied as solution — see labeling, —

Reconstituted2–8°C, per labeling

Supplied as a solution product
Protect from light
Do not freeze

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with Cerebrolysin

Full Cerebrolysin profile Cheapest Cerebrolysin deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.